X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals, Inc.

NNASDAQ:XFOR
2.83
USD
-0.29
(-9.29%)
-0.66EPS
292.62MMarket Cap
Mar 23Next Earn

Total Valuation

USD

As of September 30, 2026, X4 Pharmaceuticals, Inc. carries a market capitalization of 292.62M, placing it among publicly traded companies globally. Its enterprise value stands at 182.12M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap292.62M
Enterprise Value182.12M

Important Dates

X4 Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for March 23, 2027.

Earnings Date3/23/2027

Share Statistics

As of September 30, 2026, X4 Pharmaceuticals, Inc. has 100.90M shares outstanding.

Shares Outstanding100.90M

Valuation Ratios

These figures are as of September 30, 2026. The price-to-sales ratio is 20.93, and the price-to-book ratio stands at 2.11.

PS Ratio20.93
PB Ratio2.11
P/TBV Ratio2.69
P/FCF Ratio-4.38
P/OCF Ratio-4.67

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 10.74 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 182.12M versus a market cap of 292.62M, with the gap driven by net debt and cash on the balance sheet.

EV / Sales10.74

Financial Position

As of September 30, 2026, X4 Pharmaceuticals, Inc. maintains a current ratio of 13.22, meaning it holds 13.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 55.58, indicating elevated leverage, while an interest coverage ratio of -9.06 demonstrates limited ability to service its debt obligations.

Current Ratio13.22
Quick Ratio12.62
Debt / Equity55.58
Debt / EBITDA-0.98
Interest Coverage-9.06

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, X4 Pharmaceuticals, Inc. posted a negative return on equity (ROE) of -80.32, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -40.73, reflecting losses generated across the asset base. The company generates approximately 376,911.11 in revenue per employee across its workforce of 45.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.65 indicates how many times X4 Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-80.32
Return on Assets (ROA)-40.73
Revenue Per Employee376,911.11
Employee Count45.00
Inventory Turnover0.65

Taxes

USD

Over the twelve months ended September 30, 2026, X4 Pharmaceuticals, Inc. recorded 5,000.00 in income tax expense. The company reported a pretax loss of -80.52M and -80.52M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax5,000.00

Stock Price Statistics

USD

As of the close on November 16, 2026, X4 Pharmaceuticals, Inc.'s stock has declined approximately 22.68% over the past 52 weeks. The 50-day moving average sits at 3.13, while the 200-day moving average is 3.77.

52-Week Price Change-22.68%
50-Day Moving Average3.13
200-Day Moving Average3.77

Income Statement

USD

Over the twelve months ended September 30, 2026, X4 Pharmaceuticals, Inc. generated 16.96M in revenue and converted that into -80.52M in net income, yielding earnings per share of -0.66. EBITDA reached -78.61M, while operating income came in at -80.39M.

Revenue16.96M
Gross Profit13.87M
Operating Income-80.39M
Pretax Income-80.52M
Net Income-80.52M
EBITDA-78.61M
EBIT-80.39M
Earnings Per Share (EPS)-0.66

Balance Sheet

USD

As of September 30, 2026, X4 Pharmaceuticals, Inc. holds 187.70M in cash and equivalents against 77.20M in total debt, resulting in a net debt position of -108.79M. Total book value stands at 138.88M, with working capital of 183.15M providing operational flexibility.

Cash & Cash Equivalents187.70M
Total Debt77.20M
Net Debt-108.79M
Equity (Book Value)138.88M
Book Value Per Share1.38
Working Capital183.15M

Cash Flow

USD

X4 Pharmaceuticals, Inc. produced -76.10M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -5.00M in capital expenditures, free cash flow totaled -81.10M - equivalent to -0.66 per share.

Operating Cash Flow-76.10M
Capital Expenditures-5.00M
Free Cash Flow-81.10M
FCF Per Share-0.66

Margins

Over the twelve months ended September 30, 2026, X4 Pharmaceuticals, Inc. posted a gross margin of 81.77, reflecting its pricing power and cost economics. The operating margin of -473.95 and net profit margin of -474.74 provide insight into operational efficiency.

Gross Margin81.77
Operating Margin-473.95
Pretax Margin-474.71
Profit Margin-474.74
EBITDA Margin-463.49

Dividends & Yields

These figures cover the twelve months ended September 30, 2026. Free cash flow yield is negative at -22.84: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -49.91, meaning X4 Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-49.91
FCF Yield-22.84

Stock Splits

X4 Pharmaceuticals, Inc.'s most recent stock split took place on April 28, 2025 with a 30:1 split ratio.

Last Split Date4/28/2025
Split Ratio30:1

Scores

As of September 30, 2026, X4 Pharmaceuticals, Inc. has an Altman Z-Score of -2.77, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-2.77